MAP Kinase Inhibitors – PharmaLive

Eli Lilly Shakes Up Cancer R&D Strategy

Analysts, Blockbusters, Breast Cancer, Business, Fast Track, Financials, Immunotherapies, Immuotherapies, MAP Kinase Inhibitors, MET Antibodies, Oncology, Priority Review, Product Pipelines, Rheumatoid Arthritis (RA), Shares, TGF Beta R1 Kinase Inhibitors

Eli Lilly reported an increase of 8 percent in second-quarter 2017 revenue, but the real shake-up is what the company plans to do with its pipeline.

July 25, 2017/by BioSpace